← All companies

CLLS

Cellectis S.A.

CLLS Nasdaq Biological Products, (No Diagnostic Substances) EDGAR ↗

$2.75

-0.10 -3.51%

Key statistics

from XBRL data in SEC filings

Market cap

$197M

Revenue (TTM)

—

Net income (TTM)

—

EPS (TTM)

—

P/E ratio

—

Dividend yield

—

Free cash flow

—

Cash

—

Total assets

—

Gross margin

—

52-week range

$2.48 – $5.48

Recent SEC filings

40 most recent

Annual, quarterly & current reports

6-K FORM 6-K Jul 30, 2026 6-K/A Jun 26, 2026 6-K FORM 6-K Jun 25, 2026 6-K Jun 25, 2026 6-K FORM 6-K Jun 11, 2026 6-K FORM 6-K Jun 9, 2026 6-K May 21, 2026 6-K FORM 6-K May 20, 2026 6-K FORM 6-K May 12, 2026 6-K FORM 6-K May 11, 2026 6-K May 11, 2026 6-K FORM 6-K May 4, 2026 6-K FORM 6-K Apr 27, 2026 6-K FORM 6-K Apr 13, 2026 20-F Mar 20, 2026 6-K FORM 6-K Mar 20, 2026 6-K FORM 6-K Mar 12, 2026 6-K FORM 6-K Jan 8, 2026 6-K FORM 6-K Dec 15, 2025 6-K FORM 6-K Dec 8, 2025 6-K Dec 5, 2025 6-K FORM 6-K Nov 19, 2025 6-K Nov 7, 2025 6-K FORM 6-K Nov 3, 2025 6-K FORM 6-K Oct 31, 2025 6-K Oct 17, 2025 6-K FORM 6-K Oct 16, 2025 6-K/A Oct 14, 2025 6-K FORM 6-K Oct 7, 2025 6-K FORM 6-K Aug 4, 2025 6-K Aug 4, 2025 6-K FORM 6-K Jul 28, 2025 6-K FORM 6-K Jun 26, 2025 6-K Jun 26, 2025 6-K FORM 6-K May 21, 2025 6-K May 21, 2025 6-K May 12, 2025 6-K FORM 6-K May 12, 2025 6-K FORM 6-K May 6, 2025 6-K FORM 6-K Apr 28, 2025